| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
INFLAMMATION AND INFLAMMATORY BOWEL DISEASE |
1 Division of Gastroenterology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine Cleveland, Ohio, USA, and Department of Internal Medicine, Catholic University of Rome, Rome, Italy
2 Division of Gastroenterology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine Cleveland, Ohio, USA
3 Gastroenterology and Gastrointestinal Endoscopy Service, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
4 Department of Internal Medicine, Catholic University of Rome, Rome, Italy
Correspondence to:
Correspondence to:
Dr C Fiocchi, Division of Gastroenterology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine (BRB 425), 10900 Euclid Avenue, Cleveland, Ohio 44106-4952, USA;
cxf18{at}po.cwru.edu
Background: The CD40/CD40L system, a key regulator and amplifier of immune reactivity, is activated in inflammatory bowel disease (IBD) mucosa.
Aims: To determine whether plasma levels of sCD40L are elevated in Crohn’s disease (CD) and ulcerative colitis (UC) patients compared with normal controls, to investigate the cellular source of sCD40L, and to explore CD40L induction mechanisms.
Patients: CD, UC, and normal control subjects were studied.
Methods: The concentration of sCD40L in plasma and supernatants of freshly isolated platelets and autologous peripheral blood T cells (PBT) was measured by ELISA. Surface CD40L expression level was measured by flow cytometry in resting and thrombin activated platelets, and unstimulated and CD3/CD28 stimulated PBT before and after coculture with human intestinal microvascular endothelial cells (HIMEC).
Results: Compared with normal controls, plasma sCD40L levels were significantly higher in both CD and UC patients and proportional to the extent of mucosal inflammation. Platelets from IBD patients displayed a significantly higher surface CD40L expression than those from control subjects, and released greater amounts of sCD40L than autologous PBT. Contact with IL-1ß activated HIMEC induced significant upregulation of CD40L surface expression and release by platelets.
Conclusions: Elevated levels of sCD40L in the circulation of IBD patients reflect enhanced surface expression and release of CD40L by platelets. This phenomenon translates to an increased platelet activation state apparently induced by passage through an inflamed mucosal microvascular bed, a conclusion supported by the positive correlation of plasma sCD40L levels with the extent of anatomical involvement by IBD. These results suggest that platelet-endothelial interactions critically contribute to activation of the CD40 pathway in IBD.
Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; platelets; CD40 ligand
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; sCD40L, soluble CD40 ligand; HIMEC, human intestinal microvascular endothelial cells; PBT, peripheral blood T cells; CAM, cell adhesion molecule; ICAM-1, intercellular CAM 1; VCAM-1, vascular CAM 1; HIF, human intestinal fibroblasts; IL, interleukin
Relevant Article
Gut 2003 52: 1391.
This article has been cited by other articles:
|
|
 |
|
  L. Deban, C. Correale, S. Vetrano, A. Malesci, and S. Danese Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades Am. J. Pathol., June 1, 2008; 172(6): 1457 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Danese, F Scaldaferri, S Vetrano, T Stefanelli, C Graziani, A Repici, R Ricci, G Straface, A Sgambato, A Malesci, et al. Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease Gut, September 1, 2007; 56(9): 1248 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leveille, M. Bouillon, W. Guo, J. Bolduc, E. Sharif-Askari, Y. El-Fakhry, C. Reyes-Moreno, R. Lapointe, Y. Merhi, J. A. Wilkins, et al. CD40 Ligand Binds to {alpha}5beta1 Integrin and Triggers Cell Signaling J. Biol. Chem., February 23, 2007; 282(8): 5143 - 5151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fujimi, M. P. MacConmara, A. A. Maung, Y. Zang, J. A. Mannick, J. A. Lederer, and P. H. Lapchak Platelet depletion in mice increases mortality after thermal injury Blood, June 1, 2006; 107(11): 4399 - 4406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Danese, M. Sans, F. Scaldaferri, A. Sgambato, S. Rutella, A. Cittadini, J. M. Pique, J. Panes, J. A. Katz, A. Gasbarrini, et al. TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease J. Immunol., February 15, 2006; 176(4): 2617 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Santilli, G. Davi, A. Consoli, F. Cipollone, A. Mezzetti, A. Falco, T. Taraborelli, E. Devangelio, G. Ciabattoni, S. Basili, et al. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., January 17, 2006; 47(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schmitt-Sody, A. Klose, O. Gottschalk, P. Metz, H. Gebhard, S. Zysk, M. E. Eichhorn, T. M. Hernandez-Richter, V. Jansson, and A. Veihelmann Platelet endothelial cell interactions in murine antigen-induced arthritis Rheumatology, July 1, 2005; 44(7): 885 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Danese, M Sans, and A Gasbarrini CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems Gut, June 1, 2005; 54(6): 891 - 892. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mori, J. W. Salter, T. Vowinkel, C. F. Krieglstein, K. Y. Stokes, and D. N. Granger Molecular determinants of the prothrombogenic phenotype assumed by inflamed colonic venules Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G920 - G926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Danese, M Sans, and C Fiocchi The CD40/CD40L costimulatory pathway in inflammatory bowel disease Gut, July 1, 2004; 53(7): 1035 - 1043. [Full Text] [PDF]
|
|
|
|
|
|
S. Danese, C. de la Motte, B. M. R. Reyes, M. Sans, A. D. Levine, and C. Fiocchi Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification J. Immunol., February 15, 2004; 172(4): 2011 - 2015. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
